Can you identify keytruda's patent owner?

Who owns the patent for Keytruda?

As of my knowledge cutoff, Keytruda's active patent holders are Merck Sharp & Dohme Corp. (also known as MSD), a subsidiary of Merck & Co., Inc. [1]

Why is Merck Sharp & Dohme Corp. the patent holder for Keytruda?

Merck Sharp & Dohme Corp. is the owner of the patent for Keytruda, also known as pembrolizumab, primarily due to its original development and research. Keytruda was first approved by the U.S. FDA in 2014 for the treatment of metastatic melanoma [2] and has since been approved for various other indications, including non-small cell lung cancer, head and neck cancer, and others.

Timeline of patent ownership and expiration

According to DrugPatentWatch.com [3], Keytruda's U.S. patent (U.S. Patent No. 8,795,996) expired on December 20, 2023. However, patents in other countries may still be in effect.

Merck Sharp & Dohme Corp.'s market exclusivity

The expiration of Keytruda's U.S. patent will allow other manufacturers to produce and sell biosimilars of Keytruda, which could potentially reduce its market share and impact its sales.

Future developments and implications

As other companies develop biosimilars of Keytruda, competition may increase, and prices may decrease. This could have implications for patients, the healthcare system, and pharmaceutical companies alike.

Sources:

[1] Merck Sharp & Dohme Corp. - Official Website
[2] U.S. FDA - Keytruda Approval History
[3] DrugPatentWatch.com - Keytruda Patent Expiration